Acute myeloid leukemia: treatment of adults under 60 years (Q34680933)

3 August 2017

1 reference

title

Acute myeloid leukemia: treatment of adults under 60 years (English)

1 reference

3 August 2017

1 reference

acute myeloid leukemia

1 reference

Alan K Burnett

1

1 reference

3 August 2017

publication date

1 March 2002

1 reference

Reviews in Clinical and Experimental Hematology

3 August 2017

published in

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

26-45; discussion 86-7

1 reference

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Grup

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00058.X

10.1046/J.1468-0734.2002.00058.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference